LOC646021 Inhibitors
LY294002 and PD98059 are compounds that can inhibit key signaling molecules PI3K and MEK1/2, respectively. Disruption of these enzymatic activities by these inhibitors can lead to alterations in the PI3K/Akt and MAPK/ERK pathways, which are fundamental to cell proliferation and survival. Rapamycin and Bortezomib represent inhibitors that can target mTOR and the ubiquitin-proteasome system, each a crucial node in the regulation of cell growth and protein turnover. SB203580 and SP600125 can inhibit p38 MAP kinase and JNK, modulating stress responses and apoptosis.
U0126, like PD98059, can inhibit MEK and thus impact the MAPK/ERK pathway. PP2, Dasatinib, and Gefitinib can alter signaling processes by targeting Src-family kinases, BCR-ABL, and EGFR, respectively. Such changes in tyrosine kinase activity can have broad implications for signal transduction networks. Sorafenib and Imatinib offer broader kinase inhibition, affecting multiple kinases and potentially leading to a wide array of alterations in cellular signaling.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of PI3K, which can disrupt PI3K/Akt signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK1/2, which can inhibit the MAPK/ERK pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor, which can disrupt mTOR signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A specific inhibitor of p38 MAP kinase, which can affect the p38 MAPK stress response pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
An inhibitor of JNK, which can influence the JNK signaling pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A MEK inhibitor, which can affect the MAPK/ERK pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
An Src-family tyrosine kinase inhibitor, which can modulate signaling cascades involving these kinases. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
An inhibitor of BCR-ABL and Src-family kinases, which can alter associated signaling pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
An EGFR tyrosine kinase inhibitor, which can affect signaling through the EGFR pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor, which can disrupt protein degradation pathways. | ||||||